Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey.,Respiratory Medicine

当前位置： X-MOL 学术 › Resp. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey.
Respiratory Medicine ( IF 3.5 ) Pub Date : 2020-06-08 , DOI: 10.1016/j.rmed.2020.106062
Pedro Mondejar-Lopez ₁ , Esther Quintana-Gallego ₂ , Rosa M Giron-Moreno ₃ , Isidoro Cortell-Aznar ₄ , Marta Ruiz de Valbuena-Maiz ₅ , Layla Diab-Caceres ₆ , Concepcion Prados-Sanchez ₇ , Antonio Alvarez-Fernandez ₈ , Patricia W Garcia-Marcos ₉ , Carlos Peñalver-Mellado ₁₀ , M Dolores Pastor-Vivero ₁₁ , Casilda Olveira ₁₂ , Alejandro Lopez-Neyra ₁₃ , Silvia Castillo-Corullon ₁₄ , Samara Palma-Milla ₁₅ , Estela Perez-Ruiz ₁₆ , Amparo Sole-Jover ₁₇ , M Isabel Barrio ₅ , Manuel Sanchez-Solis ₁₈ , Óscar Asensio de la Cruz ₁₉ ,

Affiliation

Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain; Department of Surgery, Paediatrics, Obstetrics and Genecology, Universidad de Murcia, Spain.
Cystic Fibrosis Unit, Medical-Surgical Unit for Respiratory Diseases, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío, Sevilla, Spain; Centre for Biomedical Research Network of Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Cystic Fibrosis and Bronchiectasis Unit, Instituto de Investigacion, Hospital Universitario de la Princesa, Madrid, Spain.
Pediatric Pulmonology and Allergy Unit, Cystic Fibrosis Unit, Hospital Universitari i Politecnic La Fe, Valencia, Spain.
Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Universitario La Paz, Madrid, Spain.
Adult Cystic Fibrosis Unit, Pulmonology Service, Hospital Universitario 12 de Octubre, Madrid, Spain.
Pulmonology Service, Cystic Fibrosis and Bronchiectasis Unit, Hospital Universitario La Paz, Madrid, Spain.
Adult Cystic Fibrosis Unit, Pulmonology Service, Hospital Vall D'Hebron, Barcelona, Spain; Vall D'Hebron Institut de Recerca, Barcelona, Spain.
Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain.
Pulmonology Service. Hospital Clinico Universitario Virgen de La Arrixaca, Murcia, Spain.
Osakidetza. Organización Sanitaria Integrada Ezkerraldea-Enkarterri-Cruces, Hospital Universitario Cruces, Paediatrics, Cystic Fibrosis Unit, Bizkaia, Spain.
Cystic Fibrosis and Bronchiectasis Unit, Pulmonology Service, Hospital Regional Universitario, Malaga, Spain; Biomedical Research Institute of Malaga (IBIMA), Universidad de Malaga, Spain.
Cystic Fibrosis Unit, Pediatrics Service, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Clínico Universitario, Valencia, Spain.
Endocrinology and Nutrition Service, Cystic Fibrosis Unit, Hospital Universitario La Paz, Madrid, Spain.
Cystic Fibrosis and Bronchiectasis Unit, Pulmonology Service, Hospital Regional Universitario, Malaga, Spain; Pediatric Pulmonology and Cystic Fibrosis Unit, UGC de Pediatría, Hospital Regional Universitario, Málaga, Spain.
Lung Transplantation and Cystic Fibrosis Unit, Hospital Universitario La Fe, Universidad de Valencia, Valencia, Spain.
Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain; Department of Surgery, Paediatrics, Obstetrics and Genecology, Universidad de Murcia, Spain; Biomedical Research Institute of Murcia (IMIB), Murcia, Spain.
Cystic Fibrosis Unit, Pediatric Pulmonology and Allergy Unit, Hospital Universitari Parc Tauli, Sabadell, Barcelona, Spain; Faculty of Medicine, Universidad Autonoma de Barcelona, Spain.

Background

Given the high incidence of confirmed infection by SARS-CoV-2 and mortality by COVID-19 in the Spanish population, its impact was analysed among persons with Cystic Fibrosis (CF) as a group at risk of a worse evolution. The possible causes of the incidence observed in them are explained and how CF Units have faced this health challenge is detailed.

Methods

Retrospective descriptive observational study, for which a Spanish CF Patients with Confirmed COVID-19 Registry is created, requesting information on number of people affected between 8 March–16 May 2020 and their clinical-demographic characteristics from the CF Units participating in the European Cystic Fibrosis Society Patient Registry (ECFSPR). The accumulated incidence is calculated, compared with that of the general population. Additionally, a survey (CF-COVID19-Spain) is carried out on prevention of SARS-CoV-2 infection, workings of CF Units and possible reasons for the incidence observed.

Results

COVID-19 was diagnosed in eight CF patients, one of whom had received a lung transplant. The accumulated incidence was 32/10000 in CF patients and 49/10000 in the general population. General death rate was 5.85/10000 while no CF patients included in the ECFSPR died. The characteristics of those affected and the results of the survey are described.

Conclusions

Despite being considered a disease at high risk of severe COVID-19, the low incidence and mortality in CF patients in Spain contrasts with the figures for the general population. The possible factors that would explain such findings are discussed, with the help of the results of the CF-COVID19-Spain survey.

中文翻译：

SARS-CoV-2 感染对西班牙囊性纤维化患者的影响：全国 CF-COVID19-西班牙调查的发生率和结果。

背景

鉴于西班牙人群中 SARS-CoV-2 确诊感染的高发病率和 COVID-19 的死亡率，分析了其对囊性纤维化 (CF) 人群的影响，该人群有恶化发展的风险。解释了其中观察到的发病率的可能原因，并详细说明了 CF 单位如何面对这一健康挑战。

方法

回顾性描述性观察研究，为此创建了西班牙 CF 患者确诊 COVID-19 登记处，要求提供有关 2020 年 3 月 8 日至 5 月 16 日期间受影响的人数及其来自参与欧洲囊性纤维化的 CF 单位的临床人口学特征的信息协会患者登记处(ECFSPR)。计算累积发病率，并与一般人群进行比较。此外，还对预防 SARS-CoV-2 感染、CF 装置的工作情况以及观察到的发病率的可能原因进行了调查 (CF-COVID19-Spain)。